Antibodies induced by vaccination with purified chick embryo cell culture vaccine (PCECV) cross-neutralize non-classical bat lyssavirus strains (Q39823763)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Antibodies induced by vaccination with purified chick embryo cell culture vaccine (PCECV) cross-neutralize non-classical bat lyssavirus strains	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Antibodies induced by vaccination with purified chick embryo cell culture vaccine (PCECV) cross-neutralize non-classical bat lyssavirus strains (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

1 reference

based on heuristic

inferred from title

3

object named as

Noël Tordo

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

author name string

Claudius Malerczyk

1

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Thomas Selhorst

2

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Susan Moore

4

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Thomas Müller

5

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

language of work or name

0 references

publication date

16 July 2009

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

5320-5325

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Australian bat lyssavirus infection: a second human case, with a long incubation period

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Characterisation of a novel lyssavirus isolated from Pteropid bats in Australia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Phylogenetic relationships of Irkut and West Caucasian bat viruses within the Lyssavirus genus and suggested quantitative criteria based on the N gene sequence for lyssavirus genotype definition

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Isolation of Lagos bat virus from water mongoose

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

European bat Lyssavirus transmission among cats, Europe

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

European bat lyssaviruses: an emerging zoonosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Fatal encephalitis caused by a bat-borne rabies-related virus. Clinical findings

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Case report: isolation of a European bat lyssavirus type 2a from a fatal human case of rabies encephalitis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Isolation of EBLV-2 in a Daubenton's bat (Myotis daubentonii) found in Oxfordshire

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

First isolation of EBLV-2 in Germany

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Epidemiology of bat rabies in Germany.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine: serological and clinical responses in man.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Human diploid cell culture rabies vaccine (HDCV) and purified chick embryo cell culture rabies vaccine (PCECV) both confer protective immunity against infection with the silver-haired bat rabies virus strain (SHBRV).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Efficacy of rabies biologics against new lyssaviruses from Eurasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Human rabies vaccines induce neutralising antibodies against the European bat rabies virus (Duvenhage)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Susceptibility of domestic dogs and cats to Australian bat lyssavirus (ABLV).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Structure and expression in baculovirus of the Mokola virus glycoprotein: an efficient recombinant vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Effective postexposure treatment of rabies-infected sheep with rabies immune globulin and vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Rabies antibody levels in bat handlers in the United Kingdom: immune response before and after purified chick embryo cell rabies booster vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

Chimeric lyssavirus glycoproteins with increased immunological potential

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.095

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.06.095

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39823763&oldid=2090957254"